Millennium Management LLC Cuts Stock Position in BioAtla, Inc. (NASDAQ:BCAB)

Millennium Management LLC lowered its stake in BioAtla, Inc. (NASDAQ:BCAB) by 58.8% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,095,606 shares of the company’s stock after selling 1,563,983 shares during the period. Millennium Management LLC owned 2.27% of BioAtla worth $648,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in BCAB. Norges Bank purchased a new stake in shares of BioAtla in the 4th quarter worth approximately $230,000. Highbridge Capital Management LLC purchased a new stake in shares of BioAtla in the 4th quarter worth approximately $1,484,000. Renaissance Technologies LLC lifted its position in BioAtla by 62.2% in the 4th quarter. Renaissance Technologies LLC now owns 829,596 shares of the company’s stock valued at $490,000 after acquiring an additional 318,196 shares in the last quarter. Jane Street Group LLC lifted its position in BioAtla by 204.1% in the 4th quarter. Jane Street Group LLC now owns 149,291 shares of the company’s stock valued at $88,000 after acquiring an additional 100,204 shares in the last quarter. Finally, Boxer Capital Management LLC bought a new position in BioAtla in the 4th quarter valued at approximately $406,000. Hedge funds and other institutional investors own 77.23% of the company’s stock.

BioAtla Stock Performance

Shares of BCAB stock opened at $0.48 on Friday. BioAtla, Inc. has a 52-week low of $0.24 and a 52-week high of $2.53. The firm has a market capitalization of $28.15 million, a PE ratio of -0.28 and a beta of 0.92. The stock has a fifty day simple moving average of $0.40 and a two-hundred day simple moving average of $0.59.

BioAtla (NASDAQ:BCAB) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.01). On average, sell-side analysts forecast that BioAtla, Inc. will post -1.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BCAB has been the topic of several analyst reports. HC Wainwright reaffirmed a “neutral” rating on shares of BioAtla in a research report on Monday, March 31st. Wall Street Zen raised BioAtla from a “sell” rating to a “hold” rating in a research report on Friday.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.